

臺北醫學大學 泌尿腎臟研究中心 會議記錄

時間:112年3月23日(星期四)14:00-15:00

地點:視訊會議-(請以正式全名登入會議室,以利進行會議簽到)

使用 Google Meet (會議前 10 分鐘即開啟會議室)

會議室連結: https://meet.google.com/wdk-bxsc-qza

(敬略稱位)

會議主席: 吳麥斯

與會人員:

【附醫】劉明哲、葉劭德、吳建志、林孝友、吳政誠、張景欣、陳偉傑、 顧芳瑜、羅詩修、方德昭、陳錫賢、林彦仲、吳岳霖、高治圻、 陳靜怡、葉曙慶、戴定恩

【萬芳】溫玉清、李良明、林克勳、林雍偉、蕭志豪、許軒豪、賴宗豪、 鄭仲益、陳作孝、蘇裕謀、劉崇德、楊韻紅、李明哲、鍾卓興

【雙和】吳佳璋、陳冠州、劉家宏、江怡德、鄒凱亦、高偉棠、胡書維、 魏汶玲、吳美儀、洪麗玉、鄭彩梅、邱怡仁、陳佑瑋、廖家德、 游博翰、陳正憲、邱惠雯


【新國民】許永和、鄒居霖

長官指導:

林建煌校長、李岡遠研發長、許志成教授、崔克宏副院長、陳瑞明所長

議程:

一、功能性泌尿團隊、急性腎病團隊 小組報告






2023 臺北醫學大學泌尿腎臟研究中心

例會報告: Female Stress Urinary Incontinence

單 位:功能性泌尿中心

報告人:雙和醫院 胡書維醫師

2023/03/23






Female Stress Urinary Incontinence

 The complaint of any involuntary loss of urine on effort of physical exertion (e.g. sporting activities) or on sneezing or coughing.







DelLancey:

Level 1: the uterosacral ligament and the cardinal ligament

Level 2: the pubocervical and rectovaginal fascia as part of the paracolpium

Level 3: the superficial transvers perineal muscle and the urethra

Treatments of Female SUI

- Non-surgical
- Surgical
- Cell therapy



Non-Surgical Treatment for Female SUI

Device	Reported efficacy in SUI improvement	Advantages	Disadvantages	Cost	Photo
Pelvic Floor Strengthening					
Vaginal Cone	~70% [11]	Simple to use	Placement may be difficult with vaginal atrophy	\$25-\$50	25g (3.8xr) 40g (4.8xr) (3.7xr) (105) (4.8xr) (3.7xr)
Biofeedback (Elvie®, FemFit®, Perifit®, leva®)	87% [19]	Real time feedback	Requires smart phone, unclear accuracy	\$150-\$650	
Intravaginal Electrical Stimulation (ïTouch Sure)	50-60% [25]	Well-tolerated	Increased risk of vaginal and urinary tract infec- tions		
Combination biofeedback and intravaginal stimulation (InTone®, Attain)	68% [26]	Well-tolerated, easy device usability, over the counter		\$349	
Current Urology Reports (2022) 23:185–194					

Non-Surgical Treatment for Female SUI

Photo Device Advantages Disadvantages Cost Reported efficacy in SUI improvement Pelvic Floor Strengthening External Electrical 60-70% [25] Non-invasive Pain / discomfort \$400 - \$450 Stimulation (INNOVO®, ELITONE®) \$1000 - \$3000 for 6 sessions Magnetic Stimulation Non-invasive, keep clothes on Must travel to a clinic (Extracorporeal magnetic or~\$400/session innervation, High Intensity Focused Electromagnetic Field)

Current Urology Reports (2022) 23:185-194




Treatments of Female SUI

- Non-surgical
- Surgical
- Cell therapy

Surgical Treatment for Female SUI

Midurethral Sling Surgery



TMU 北黒六十 酒向榮耀

-

Treatments of Female SUI

- Non-surgical
- Surgical
- Cell therapy

Cell Therapy in Female SUI



Frontiers | Frontiers in Cell and Developmental Biology

YPE Review PUBLISHED 08 February 2023 oı 10.3389/fcell.2023.1090386

Advances in the molecular pathogenesis and cell therapy of stress urinary incontinence

Xiao-xiao Wang, Lei Zhang and Ye Lu*

Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China

- Stem cells
- Exosomes
- Regulation of gene expression
- → The specific molecular pathogenic mechanisms of SUI are still unclear.

Front Cell Dev Biol. 2023 Feb 8;11:1090386



三院Female SUI治療及研究願景

- ✓設置骨盆健康中心:配備biofeedback/電刺激/ 磁波椅/低能量體外震波等非侵襲性尿失禁治 療儀器,另外依序引進PRP、陰道雷射及尿道 注射等多樣治療。
- ✓增加婦女泌尿次專醫師及認證專家人數,進 而增加三院婦女泌尿治療量能。

雙和: 陳冠州醫師、胡書維醫師(已送件)

北醫:吳政誠醫師



雙和醫院震波暨骨盆健康中心











16

三院Female SUI治療及研究願景

✓將臨床和基礎醫學做結合,三院合作收案進行相關研究。

可進行之研究面向:

- PRP/ Li-ESWT monotherapy or combination therapy
- PRP/Li-ESWT after surgery or combination with surgery
- 3) Molecular pathogenesis of female SUI
- 4) Cell therapy combined with PRP/Li-ESWT





日期: 2023/02/22 功能泌尿組聚餐



RCUK AKD center 報告

CHEN YU-WEI 2023/03/23

Current research projects

- Analysis of AKI eAlert responses
- Analysis of AKI eAlert in other hospitals
- Modification of AKI eAlert system
- Embedment of AKI-AKD-CKD electronic system in TMU3.0
- Weaning from dialysis protocol

_

內建式計算器進行連續性靜脈對靜脈血液過濾術處方最佳化以改善重症急 性腎損傷病患治療品質

Built-in calculator optimizes continuous veno-venous hemofiltration prescription to improve therapeutic quality in critically-ill acute kidney injury patients

吳浩銘1,2*, <u>陳佑瑋</u>3,4,5,6*, 吳美儀3,4,6, 廖家德3,4,6, 鄭彩梅3,4,6, 林裕峯3,4,5, 邱怡仁3,4,6, 洪麗玉3,6, 葉兩婷7, 曾健華8, 程毅君9,10,許永和3,4,5,6**, 吳麥斯3,4,5,6***

I臺北醫學大學雙和醫院教學部2國立成功大學醫學院附設醫院教學中心3臺北醫學大學雙和醫院內科部腎臟內科4臺北醫學大學醫學院醫學系腎臟內科學科5臺北醫學大學醫學院施床醫學研究所6臺北醫學大學逐次腎臟研究中心7臺北醫學大學雙和醫院資訊室8臺北醫學大學雙和醫院金重症醫學部9臺北醫學大學雙和醫院在開部10臺北醫學大學醫學院在開學科◆共同第一作者◆結構訊作者

Keys to successful CVVH 49

CVVH Treatment Effect Adequate CVVH Dosage Higher

Total UF 25-35ml/kg/h

Continuous Treatment Time

Lower

Filtration fraction 20-25%

Calculating evidence-based renal replacement therapy – Introducing an excel-based calculator to improve prescribing and delivery in renal replacement therapy – A before and after study





Patients received CVVHDF during 2012 Jan. ~ Jun.



Excel-based dose calculator to keep at 25 ml/kg/h



Limited FF to 15%



Treatment variation, Order changing, Filter lifespan

Advantages of FF control:



+13.7 h
average filter lifespan



- 519 £ in every 24 hrs period



- 25% order changing

Limitation:



Only 15 patients and 28 sessions were studied



Difficult to update. Non-sync patient data.




Lack data of downtime, clotting, circuit pressure

Conclusion: Excel-based dose calculator reduced variation in prescriptions, and the control of filtration fraction prolonged filter lifespan and saved medical expenses.


Cottle et al. J Intensive Care Soc. 2016 Feb;17(1):44-50. doi: 10.1177/1751143715603383


CVVH Prescription Calculators



Built-in calculator optimizes CVVH prescription and improves therapeutic quality in critically-ill AKI patients







Conclusion:

Utilization of a built-in FF calculator reduced calculation barriers, improved treatment quality, reduced medical expenses, and saved lives.

Hao-Ming Wu, Yu-Wei Chen, et al Unpublished data, Manuscript in preparation Dec. 10th, 2022

Built-in calculator optimizes CVVH prescription and improves therapeutic quality in critically-ill AKI patients





Patients recieved CVVH in ICU during 2019~2021 470 patients & 793 sessions



Built-in CVVH calculator utilization since 2020.10.01



Filter clotting, Filter lifespan Mortality

Outcomes:



10% +5

lotting average filte



- **61,600**_{NTD}

in every 10 CVVH sessions



-10%

Death in ICU (30 & 60 days)

Conclusion:

Utilization of a built-in FF calculator reduced calculation barriers, improved treatment quality, reduced medical expenses, and saved lives.

Hao-Ming Wu, Yu-Wei Chen, et al Unpublished data, Manuscript in preparation Dec. 10th, 2022

10

Before group

Built-in Calculator



After group



Filter Lifespan



衛生福利部雙和醫院









雙和醫院



萬芳 醫院



北醫 附醫



新國民 醫院

Thanks for your attention!

Together we can help our AKI/AKD/CKD patients!

群策群力,共進急性腎病照護!

12